ArticleDiscover nano2026
Characterization of zinc oxide and iron oxide nanoparticles stabilized with morin hydrate, and investigation and comparison of their antioxidant, antimicrobial, apoptotic, and anticarcinogenic properties.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to synthesize and characterize morin hydrate-stabilized ZnO and FeO nanoparticles and to compare their antioxidant, antimicrobial, apoptotic, and anticarcinogenic properties in in vitro models. The data obtained from this study, through biological evaluations and various characterizations, can contribute to the development of new nanotherapy methods against various infectious diseases and cancer. The synthesized nanoparticles were characterized by UV-Visible spectrophotometry (UV-Vis), Fourier transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), and energy dispersive X-ray (EDX). The antimicrobial activity of these nanoparticles against gram-negative (E. coli ATCC 11229, K. pneumoniae ATCC 13883, S. aureus ATCC 25923, P. aeruginosa ATCC 9027), gram-positive (S. aureus ATCC 25923), and fungal (C. albicans ATCC 10231) strains was evaluated. Antioxidant capacity analyses were performed using DPPH, FRAP, and CUPRAC methods. The cytotoxic effects of nanoparticles were investigated in the HCT-116 colon cancer cell line. Cell viability and apoptosis markers were assessed using AO/EB staining, Annexin-V/Propidium Iodide (PI) staining, and flow cytometry, and cell populations were quantitatively separated. In the UV-Vis spectrum, MrZnO exhibited a broader absorption peak at approximately 300 nm, while MrFeO exhibited a broader absorption peak at approximately 350 nm. FTIR spectra (MrZnO-MrFeO) were recorded to determine the functional groups of the biomolecules involved in the synthesis. In SEM images, MrZnO showed a uniform size distribution, rectangular prism morphology, low aggregation, and smooth surface properties, while MrFeO showed a uniform size distribution and negligible aggregation properties. While MrZnO exhibited a broad spectrum of activity, MrFeO nanoparticles exhibited a narrower spectrum of activity and a more limited overall antimicrobial potential compared to MrZnO. MrFeO (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.